OncoMatch/Clinical Trials/NCT04690348
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
Is NCT04690348 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for recurrent brain metastases.
The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
resection of a previously-irradiated brain metastasis with suspicion for viable disease
Prior therapy
Must have received: radiation therapy — site of brain metastasis
resection of a previously-irradiated brain metastasis
Cannot have received: radiation therapy
Prior irradiation (EQD2) in excess of 100 Gy to site of implant, using an α/β of 2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Baptist Health South Florida · Miami, Florida
- Memorial Sloan Kettering at Basking Ridge (Consent Only) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only) · Middletown, New Jersey
- Memorial Sloan Kettering Commack (Consent Only) · Commack, New York
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify